Forest/Adamas seek US OK for memantine-donepezil FDC in Alzheimer's
This article was originally published in Scrip
Executive Summary
Forest Laboratories, which is being acquired by Actavis, submitted a new drug application (NDA) to the FDA for a fixed-dose combination (FDC) of memantine HCl extended-release (ER) and donepezil as a treatment for moderate to severe dementia of the Alzheimer's type.